Trials / Active Not Recruiting
Active Not RecruitingNCT06947850
DOMPE -MT Neurotrophic Keratitis
TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment With Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Toyos Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment with Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cenegermin Ophthalmic Solution [Oxervate] | Oxervate (cenegermin-bkbj) is commonly used to treat neurotrophic keratitis |
Timeline
- Start date
- 2023-01-21
- Primary completion
- 2025-09-25
- Completion
- 2025-09-25
- First posted
- 2025-04-27
- Last updated
- 2025-04-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06947850. Inclusion in this directory is not an endorsement.